论文部分内容阅读
近一个世纪以来,尝试过注射由不同动物制备的抗血清的特异被动免疫制剂来治疗癌症,一般均未取得成功。随着杂交瘤技术和小鼠单克隆抗体(MAbs)的问世,能够进行更系统的研究,并且大部分特异性被动免疫血清疗法的研究集中在血液恶性变的治疗上,其中包括25批135例患者的临床试验。完全缓解、部分缓解和轻微好转率分别为5％,16％,17％。然而,这种缓解常是暂时的。尽管用未结合的单克隆抗体治疗效果令人失望,但它们还是丰富了我们对所遇到的问题及这些抗体如何发挥抗肿瘤作用的认识。
For nearly a century, attempts to treat cancer by injecting specific passive immunization preparations of antiserum prepared from different animals have generally failed. With the advent of hybridoma technology and mouse monoclonal antibodies (MAbs), more systematic studies can be conducted, and most of the studies of specific passive immune serum therapy focused on the treatment of hematological malignancy, including 25 batches of 135 cases. Patients’ clinical trials. The complete, partial and minor improvement rates were 5%, 16%, and 17%, respectively. However, this relief is often temporary. Despite disappointing results with unconjugated monoclonal antibodies, they still enriched our understanding of the problems encountered and how these antibodies exert their anti-tumor effects.